Identification of Driver and Passenger Mutations of FLT3 by High-Throughput DNA Sequence Analysis and Functional Assessment of Candidate Alleles

Stefan Fröhling, Claudia Scholl, Ross L. Levine, Marc Loriaux, Titus J. Boggon, Olivier A. Bernard, Roland Berger, Hartmut Döhner, Konstanze Döhner, Benjamin L. Ebert, Sewit Teckie, Todd R. Golub, Jingrui Jiang, Marcus M. Schittenhelm, Benjamin H. Lee, James D. Griffin, Richard M. Stone, Michael Heinrich, Michael W. Deininger, Brian DrukerD. Gary Gilliland

Research output: Contribution to journalArticle

127 Citations (Scopus)

Abstract

Mutations in the juxtamembrane and kinase domains of FLT3 are common in AML, but it is not known whether alterations outside these regions contribute to leukemogenesis. We used a high-throughput platform to interrogate the entire FLT3 coding sequence in AML patients without known FLT3 mutations and experimentally tested the consequences of each candidate leukemogenic allele. This approach identified gain-of-function mutations that activated downstream signaling and conferred sensitivity to FLT3 inhibition and alleles that were not associated with kinase activation, including mutations in the catalytic domain. These findings support the concept that acquired mutations in cancer may not contribute to malignant transformation and underscore the importance of functional studies to distinguish "driver" mutations underlying tumorigenesis from biologically neutral "passenger" alterations.

Original languageEnglish (US)
Pages (from-to)501-513
Number of pages13
JournalCancer Cell
Volume12
Issue number6
DOIs
StatePublished - Dec 6 2007

Fingerprint

DNA Sequence Analysis
Alleles
Mutation
Phosphotransferases
Catalytic Domain
Carcinogenesis
Neoplasms

Keywords

  • CELLCYCLE

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Oncology

Cite this

Identification of Driver and Passenger Mutations of FLT3 by High-Throughput DNA Sequence Analysis and Functional Assessment of Candidate Alleles. / Fröhling, Stefan; Scholl, Claudia; Levine, Ross L.; Loriaux, Marc; Boggon, Titus J.; Bernard, Olivier A.; Berger, Roland; Döhner, Hartmut; Döhner, Konstanze; Ebert, Benjamin L.; Teckie, Sewit; Golub, Todd R.; Jiang, Jingrui; Schittenhelm, Marcus M.; Lee, Benjamin H.; Griffin, James D.; Stone, Richard M.; Heinrich, Michael; Deininger, Michael W.; Druker, Brian; Gilliland, D. Gary.

In: Cancer Cell, Vol. 12, No. 6, 06.12.2007, p. 501-513.

Research output: Contribution to journalArticle

Fröhling, S, Scholl, C, Levine, RL, Loriaux, M, Boggon, TJ, Bernard, OA, Berger, R, Döhner, H, Döhner, K, Ebert, BL, Teckie, S, Golub, TR, Jiang, J, Schittenhelm, MM, Lee, BH, Griffin, JD, Stone, RM, Heinrich, M, Deininger, MW, Druker, B & Gilliland, DG 2007, 'Identification of Driver and Passenger Mutations of FLT3 by High-Throughput DNA Sequence Analysis and Functional Assessment of Candidate Alleles', Cancer Cell, vol. 12, no. 6, pp. 501-513. https://doi.org/10.1016/j.ccr.2007.11.005
Fröhling, Stefan ; Scholl, Claudia ; Levine, Ross L. ; Loriaux, Marc ; Boggon, Titus J. ; Bernard, Olivier A. ; Berger, Roland ; Döhner, Hartmut ; Döhner, Konstanze ; Ebert, Benjamin L. ; Teckie, Sewit ; Golub, Todd R. ; Jiang, Jingrui ; Schittenhelm, Marcus M. ; Lee, Benjamin H. ; Griffin, James D. ; Stone, Richard M. ; Heinrich, Michael ; Deininger, Michael W. ; Druker, Brian ; Gilliland, D. Gary. / Identification of Driver and Passenger Mutations of FLT3 by High-Throughput DNA Sequence Analysis and Functional Assessment of Candidate Alleles. In: Cancer Cell. 2007 ; Vol. 12, No. 6. pp. 501-513.
@article{a518a5f52cc7471980252c5e1cd872b3,
title = "Identification of Driver and Passenger Mutations of FLT3 by High-Throughput DNA Sequence Analysis and Functional Assessment of Candidate Alleles",
abstract = "Mutations in the juxtamembrane and kinase domains of FLT3 are common in AML, but it is not known whether alterations outside these regions contribute to leukemogenesis. We used a high-throughput platform to interrogate the entire FLT3 coding sequence in AML patients without known FLT3 mutations and experimentally tested the consequences of each candidate leukemogenic allele. This approach identified gain-of-function mutations that activated downstream signaling and conferred sensitivity to FLT3 inhibition and alleles that were not associated with kinase activation, including mutations in the catalytic domain. These findings support the concept that acquired mutations in cancer may not contribute to malignant transformation and underscore the importance of functional studies to distinguish {"}driver{"} mutations underlying tumorigenesis from biologically neutral {"}passenger{"} alterations.",
keywords = "CELLCYCLE",
author = "Stefan Fr{\"o}hling and Claudia Scholl and Levine, {Ross L.} and Marc Loriaux and Boggon, {Titus J.} and Bernard, {Olivier A.} and Roland Berger and Hartmut D{\"o}hner and Konstanze D{\"o}hner and Ebert, {Benjamin L.} and Sewit Teckie and Golub, {Todd R.} and Jingrui Jiang and Schittenhelm, {Marcus M.} and Lee, {Benjamin H.} and Griffin, {James D.} and Stone, {Richard M.} and Michael Heinrich and Deininger, {Michael W.} and Brian Druker and Gilliland, {D. Gary}",
year = "2007",
month = "12",
day = "6",
doi = "10.1016/j.ccr.2007.11.005",
language = "English (US)",
volume = "12",
pages = "501--513",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "6",

}

TY - JOUR

T1 - Identification of Driver and Passenger Mutations of FLT3 by High-Throughput DNA Sequence Analysis and Functional Assessment of Candidate Alleles

AU - Fröhling, Stefan

AU - Scholl, Claudia

AU - Levine, Ross L.

AU - Loriaux, Marc

AU - Boggon, Titus J.

AU - Bernard, Olivier A.

AU - Berger, Roland

AU - Döhner, Hartmut

AU - Döhner, Konstanze

AU - Ebert, Benjamin L.

AU - Teckie, Sewit

AU - Golub, Todd R.

AU - Jiang, Jingrui

AU - Schittenhelm, Marcus M.

AU - Lee, Benjamin H.

AU - Griffin, James D.

AU - Stone, Richard M.

AU - Heinrich, Michael

AU - Deininger, Michael W.

AU - Druker, Brian

AU - Gilliland, D. Gary

PY - 2007/12/6

Y1 - 2007/12/6

N2 - Mutations in the juxtamembrane and kinase domains of FLT3 are common in AML, but it is not known whether alterations outside these regions contribute to leukemogenesis. We used a high-throughput platform to interrogate the entire FLT3 coding sequence in AML patients without known FLT3 mutations and experimentally tested the consequences of each candidate leukemogenic allele. This approach identified gain-of-function mutations that activated downstream signaling and conferred sensitivity to FLT3 inhibition and alleles that were not associated with kinase activation, including mutations in the catalytic domain. These findings support the concept that acquired mutations in cancer may not contribute to malignant transformation and underscore the importance of functional studies to distinguish "driver" mutations underlying tumorigenesis from biologically neutral "passenger" alterations.

AB - Mutations in the juxtamembrane and kinase domains of FLT3 are common in AML, but it is not known whether alterations outside these regions contribute to leukemogenesis. We used a high-throughput platform to interrogate the entire FLT3 coding sequence in AML patients without known FLT3 mutations and experimentally tested the consequences of each candidate leukemogenic allele. This approach identified gain-of-function mutations that activated downstream signaling and conferred sensitivity to FLT3 inhibition and alleles that were not associated with kinase activation, including mutations in the catalytic domain. These findings support the concept that acquired mutations in cancer may not contribute to malignant transformation and underscore the importance of functional studies to distinguish "driver" mutations underlying tumorigenesis from biologically neutral "passenger" alterations.

KW - CELLCYCLE

UR - http://www.scopus.com/inward/record.url?scp=36649000489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36649000489&partnerID=8YFLogxK

U2 - 10.1016/j.ccr.2007.11.005

DO - 10.1016/j.ccr.2007.11.005

M3 - Article

C2 - 18068628

AN - SCOPUS:36649000489

VL - 12

SP - 501

EP - 513

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 6

ER -